22 Jan 15:02
by Caroline Williams
bioRxiv [Preprint]. 2024 Aug 27:2024.08.27.609898. doi: 10.1101/2024.08.27.609898.
ABSTRACT
Pathogenic fungi rely on the cell wall component, chitin, for critical structural and immunological functions. Here a chitin labeling method to visualize the hyphal pathogenic response was developed. The data show that filamentous fungi, Candida albicans , transport N -acetylglucosamine (NAG) bio-orthogonal probes and incorporate them into the cell wall, indicating the probes utility for in vivo study of the morphological, pathogenic switch. As yeast reside in complex microenvironments, The data show that the opportunistic microbe C. albicans , has developed processes to utilize surrounding bacterial cell wall fragments to initiate the morphogenic switch. The probes are utilized for visualization of growth patterns of pathogenic fungi, providing insights into novel mechanisms for the development of antifungals. Remodeling chitin in fungi using NAG derivatives will advance yeast pathogenic studies.
PMID:39253419 | PMC:PMC11383299 | DOI:10.1101/2024.08.27.609898
14 Oct 00:33
by Ya-Jiao Zhu, Sheng-Chen Huang, Xiao-Xia Xia, and Zhi-Gang Qian

Biomacromolecules
DOI: 10.1021/acs.biomac.4c00864
09 Oct 15:48
by M. Teresa Villanueva
Nature Reviews Drug Discovery, Published online: 08 October 2024; doi:10.1038/d41573-024-00168-3
Tumour cells get a dendritic cell makeover
09 Oct 14:06
by Kento Miyaji, Yoshiaki Masaki, and Kohji Seio

Bioconjugate Chemistry
DOI: 10.1021/acs.bioconjchem.4c00376
09 Oct 14:03
by Chengyu Yun, Na Li, Yishu Zhang, Tong Fang, Jing Ma, Zhenting Zheng, Subing Zhou, and Xiaoqing Cai

ACS Chemical Biology
DOI: 10.1021/acschembio.4c00584
07 Oct 12:54
by Michihiko Aoyama, Minoru Tada, Hidetomo Yokoo, Takahito Ito, Takashi Misawa, Yosuke Demizu, and Akiko Ishii-Watabe

Bioconjugate Chemistry
DOI: 10.1021/acs.bioconjchem.4c00348
03 Oct 14:53
by Yana D. Petri, Ruben Verresen, Clair S. Gutierrez, Volga Kojasoy, Erika Zhang, Nile S. Abularrage, Evans C. Wralstad, Kaya R. Weiser, and Ronald T. Raines

Biochemistry
DOI: 10.1021/acs.biochem.4c00446
03 Oct 14:46
by Jing Wu, Yong Zhang, Wenqi Li, Hao Tang, Ying Zhou, Di You, Xiaohe Chu, Hanbing Li, Jinsai Shang, Nan Qi, and Bang-Ce Ye

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.4c00529
03 Oct 14:46
by Pallavi Saha, Shashikanta Sau, Nitin Pal Kalia, and Deepak K. Sharma

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.4c00710
01 Oct 14:07
by Gerrit Wilms, Kevin Schofield, Shayna Maddern, Christopher Foley, Yeng Shaw, Breland Smith, L. Emilia Basantes, Katharina Schwandt, Aaron Babendreyer, Timothy Chavez, Nicholas McKee, Vijay Gokhale, Sebastian Kallabis, Felix Meissner, Samantha N. Rokey, Travis Dunckley, William R. Montfort, Walter Becker, and Christopher Hulme

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.4c01130
27 Sep 16:54
by Karolina Krygier, Anjalee N. Wijetunge, Arthur Srayeddin, Harrison Mccann, and Anthony F. Rullo

ACS Chemical Biology
DOI: 10.1021/acschembio.4c00286
27 Sep 16:54
by Yifan Dai
Nature Chemical Biology, Published online: 26 September 2024; doi:10.1038/s41589-024-01717-y
This Perspective discusses how macromolecular condensation can regulate the electrochemistry to affect biological function in living cells and provides a framework to study the electrochemical functions of biomolecular condensates.
26 Sep 16:59
by Irene Lepori
ACS Chem Biol. 2024 Oct 18;19(10):2131-2140. doi: 10.1021/acschembio.4c00250. Epub 2024 Sep 24.
ABSTRACT
Among bacteria used as anticancer vaccines, attenuated Listeria monocytogenes (Lmat) stands out, because it spreads from one infected cancer cell to the next, induces a strong adaptive immune response, and is suitable for repeated injection cycles. Here, we use click chemistry to functionalize the Lmat cell wall and turn the bacterium into an "intelligent carrier" of the chemotherapeutic drug doxorubicin. Doxorubicin-loaded Lmat retains most of its biological properties and, compared to the control fluorophore-functionalized bacteria, shows enhanced cytotoxicity against melanoma cells both in vitro and in a xenograft model in zebrafish. Our results show that drugs can be covalently loaded on the Lmat cell wall and pave the way to the development of new two-in-one therapeutic approaches combining immunotherapy with chemotherapy.
PMID:39317359 | PMC:PMC11494506 | DOI:10.1021/acschembio.4c00250
26 Sep 16:59
by Buwei Huang
Nature. 2024 Sep 25. doi: 10.1038/s41586-024-07948-2. Online ahead of print.
ABSTRACT
Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2 (LYTACs) and cytokine receptor-targeting chimeras3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand-receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody-drug and antibody-RNA conjugates.
PMID:39322662 | DOI:10.1038/s41586-024-07948-2
24 Sep 17:35
by Mariska de Munnik
Commun Biol. 2024 Sep 18;7(1):1173. doi: 10.1038/s42003-024-06785-3.
ABSTRACT
The essential L,D-transpeptidase of Mycobacterium tuberculosis (LdtMt2) catalyses the formation of 3 → 3 cross-links in cell wall peptidoglycan and is a target for development of antituberculosis therapeutics. Efforts to inhibit LdtMt2 have been hampered by lack of knowledge of how it binds its substrate. To address this gap, we optimised the isolation of natural disaccharide tetrapeptide monomers from the Corynebacterium jeikeium bacterial cell wall through overproduction of the peptidoglycan sacculus. The tetrapeptides were used in binding / turnover assays and biophysical studies on LdtMt2. We determined a crystal structure of wild-type LdtMt2 reacted with its natural substrate, the tetrapeptide monomer of the peptidoglycan layer. This structure shows formation of a thioester linking the catalytic cysteine and the donor substrate, reflecting an intermediate in the transpeptidase reaction; it informs on the mode of entrance of the donor substrate into the LdtMt2 active site. The results will be useful in design of LdtMt2 inhibitors, including those based on substrate binding interactions, a strategy successfully employed for other nucleophilic cysteine enzymes.
PMID:39294212 | PMC:PMC11410929 | DOI:10.1038/s42003-024-06785-3
19 Sep 21:08
by Yushan Xia
Nature Microbiology, Published online: 18 September 2024; doi:10.1038/s41564-024-01807-6
Bismuth-based drugs combined with antibiotics enhance efficacy against multidrug-resistant Pseudomonas aeruginosa by disrupting bacterial iron homeostasis and electron transport.
18 Sep 11:50
by Cara Adolph, Kiel Hards, Zoe C. Williams, Chen-Yi Cheung, Laura M. Keighley, William J. Jowsey, Matson Kyte, Daniel Ken Inaoka, Kiyoshi Kita, Jared S. Mackenzie, Adrie J.C. Steyn, Zhengqiu Li, Ming Yan, Guo-Bao Tian, Tianyu Zhang, Xiaobo Ding, Daniel P. Furkert, Margaret A. Brimble, Anthony J.R. Hickey, Matthew B. McNeil, and Gregory M. Cook

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.3c00655
18 Sep 11:50
by Asher Mullard
Nature Reviews Drug Discovery, Published online: 16 September 2024; doi:10.1038/d41573-024-00150-z
Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.
16 Sep 20:49
by Forrest A Hammel
J Am Chem Soc. 2024 Sep 25;146(38):26320-26330. doi: 10.1021/jacs.4c08656. Epub 2024 Sep 14.
ABSTRACT
O-GlcNAc transferase (OGT) is an essential mammalian enzyme that binds thousands of different proteins, including substrates that it glycosylates and nonsubstrate interactors that regulate its biology. OGT also has one proteolytic substrate, the transcriptional coregulator host cell factor 1 (HCF-1), which it cleaves in a process initiated by glutamate side chain glycosylation at a series of central repeats. Although HCF-1 is OGT's most prominent binding partner, its affinity for the enzyme has not been quantified. Here, we report a time-resolved Förster resonance energy transfer assay to measure ligand binding to OGT and show that an HCF-1-derived polypeptide (HCF3R) binds with picomolar affinity to the enzyme (KD ≤ 85 pM). This high affinity is driven in large part by conserved asparagines in OGT's tetratricopeptide repeat domain, which form bidentate contacts to the HCF-1 peptide backbone; replacing any one of these asparagines with alanine reduces binding by more than 5 orders of magnitude. Because the HCF-1 polypeptide binds so tightly to OGT, we tested its ability to inhibit enzymatic function. We found that HCF3R potently inhibits OGT both in vitro and in cells and used this finding to develop a genetically encoded, inducible OGT inhibitor that can be degraded with a small molecule, allowing for reversible and tunable inhibition of OGT.
PMID:39276112 | PMC:PMC11440498 | DOI:10.1021/jacs.4c08656
13 Sep 15:15
by Georg E. Winter

ACS Chemical Biology
DOI: 10.1021/acschembio.4c00191
13 Sep 10:59
by Sabareesan Ambadi Thody
Nature Chemistry, Published online: 13 September 2024; doi:10.1038/s41557-024-01630-w
Biomolecular condensates compartmentalize molecules without membranes. Understanding condensate composition is important given that their function relies on the selective exclusion or enrichment of molecules. Now, investigating small-molecule partitioning reveals variations across compounds, yet correlations indicate physical similarities between disparate condensates. Machine learning accurately predicts partitioning on the basis of physicochemical features, demonstrating the role of a hydrophobic environment in driving enrichment and exclusion.
12 Sep 14:05
by Andrea K. WegrzynowiczWilliam J. HeelanSydnye P. DemasMaxwell S. McLeanJason M. PetersKatherine A. Henzler-Wildman1Department of Biochemistry, University of Wisconsin—Madison, Madison, Wisconsin, USA2Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA3Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin—Madison, Madison, Wisconsin, USA4DOE Great Lakes Bioenergy Research Center, University of Wisconsin—Madison, Madison, Wisconsin, USA5Department of Bacteriology, University of Wisconsin—Madison, Madison, Wisconsin, USA6Department of Medical Microbiology and Immunology, University of Wisconsin—Madison, Madison, Wisconsin, USA7Center for Genomic Science Innovation, University of Wisconsin—Madison, Madison, Wisconsin, USA8National Magnetic Resonance Facility at Madison, Madison, Wisconsin, USAGeorge O'Toole
Journal of Bacteriology,
Volume 206, Issue 10, October 2024.
12 Sep 13:59
by Longcheng Guo, Oscar P. Kuipers, and Jaap Broos

ACS Chemical Biology
DOI: 10.1021/acschembio.4c00337
10 Sep 20:48
by Teresa L Rapp
J Am Chem Soc. 2024 Sep 18;146(37):25397-25402. doi: 10.1021/jacs.4c03361. Epub 2024 Sep 9.
ABSTRACT
Phototriggered release of various cargos, including soluble protein factors and small molecules, has the potential to correct aberrant biological events by offering spatiotemporal control over local therapeutic levels. However, the poor penetration depth of light historically limits implementation to subdermal regions, necessitating alternative methods of light delivery to achieve the full potential of photodynamic therapeutic release. Here, we introduce a strategy exploiting bioluminescence resonance energy transfer (BRET)-an energy transfer process between light-emitting Nanoluciferase (NLuc) and a photosensitive acceptor molecule-to drive biomolecule release from hydrogel biomaterials. Through a facile, one-pot, and high-yielding synthesis (60-70%), we synthesized a heterobifunctional ruthenium cross-linker bearing an aldehyde and an azide (CHO-Ru-N3), a compound that we demonstrate undergoes predictable exchange of the azide-bearing ligand under blue-green light irradiation (>550 nm). Following site-specific conjugation to NLuc via sortase-tag enhanced protein ligation (STEPL), the modified protein was covalently attached to a poly(ethylene glycol) (PEG)-based hydrogel via strain-promoted azide-alkyne cycloaddition (SPAAC). Leveraging the high photosensitivity of Ru compounds, we demonstrate rapid and equivalent release of epidermal growth factor (EGF) via either direct illumination or via BRET-based bioluminolysis. As NLuc-originated luminescence can be controlled equivalently throughout the body, we anticipate that this unique protein release strategy will find use for locally triggered drug delivery following systemic administration of a small molecule.
PMID:39250821 | DOI:10.1021/jacs.4c03361
10 Sep 20:47
by Jessica G K O'Brien
Chem Sci. 2024 Aug 13;15(37):15463-73. doi: 10.1039/d4sc04238g. Online ahead of print.
ABSTRACT
Dialkyldiazirines have emerged as a photo-reactive group of choice for interactome mapping in live cell experiments. Upon irradiation, 'linear' dialkyldiazirines produce dialkylcarbenes which are susceptible to both intramolecular reactions and unimolecular elimination processes, as well as diazoalkanes, which also participate in intermolecular labeling. Cyclobutylidene has a nonclassical bonding structure and is stable enough to be captured in bimolecular reactions. Cyclobutanediazirines have more recently been studied as photoaffinity probes based on cyclobutylidene, but the mechanism, especially with respect to the role of putative diazo intermediates, was not fully understood. Here, we show that photolysis (365 nm) of cyclobutanediazirines can produce cyclobutylidene intermediates as evidenced by formation of their expected bimolecular and unimolecular products, including methylenecyclopropane derivatives. Unlike linear diazirines, cyclobutanediazirine photolysis in the presence of tetramethylethylene produces a [2 + 1] cycloaddition adduct. By contrast, linear diazirines produce diazo compounds upon low temperature photolysis in THF, whereas diazo compounds are not detected in similar photolyses of cyclobutanediazirines. Diazocyclobutane, prepared by independent synthesis, is labile, reactive toward water and capable of protein alkylation. The rate of diazocyclobutane decomposition is not affected by 365 nm light, suggesting that the photochemical conversion of diazocyclobutane to cyclobutylidene is not an important pathway. Finally, chemical proteomic studies revealed that a likely consequence of this primary conversion to a highly reactive carbene is a marked decrease in labeling by cyclobutanediazirine-based probes relative to linear diazirine counterparts both at the individual protein and proteome-wide levels. Collectively, these observations are consistent with a mechanistic picture for cyclobutanediazirine photolysis that involves carbene chemistry with minimal formation of diazo intermediates, and contrasts with the photolyses of linear diazirines where alkylation by diazo intermediates plays a more significant role.
PMID:39246352 | PMC:PMC11372447 | DOI:10.1039/d4sc04238g
05 Sep 17:29
by Ashweta Sahni
J Am Chem Soc. 2024 Sep 11;146(36):25371-25382. doi: 10.1021/jacs.4c10533. Epub 2024 Sep 2.
ABSTRACT
Cell-penetrating peptides (CPPs) enter the cell by two different mechanisms-endocytosis followed by endosomal escape and direct translocation at the plasma membrane. The mechanism of direct translocation remains unresolved. In this work, the direct translocation of nonaarginine (R9) and two cyclic CPPs (CPP12 and CPP17) into Jurkat cells was monitored by time-lapse confocal microscopy. Our results provide direct evidence that all three CPPs translocate across the plasma membrane by a recently discovered vesicle budding-and-collapse (VBC) mechanism. Membrane translocation is preceded by the formation of nucleation zones. Up to four different types of nucleation zones and three variations of the VBC mechanism were observed. The VBC mechanism reconciles the enigmatic and conflicting observations in the literature.
PMID:39221867 | PMC:PMC11610503 | DOI:10.1021/jacs.4c10533
05 Sep 17:29
by Jeremy L Ritchey
Mol Pharm. 2024 Oct 7;21(10):5255-5260. doi: 10.1021/acs.molpharmaceut.4c00688. Epub 2024 Sep 2.
ABSTRACT
Intracellular delivery of biological cargos, which would yield new research tools and novel therapeutics, remains an active area of research. A convenient and potentially general approach involves the conjugation of a cell-penetrating peptide to a cargo of interest. However, linear CPPs lack sufficient cytosolic entry efficiency and metabolic stability, while previous backbone cyclized CPPs have several drawbacks including the necessity for chemical synthesis and posttranslational conjugation to peptide/protein cargos and epimerization during cyclization. We report here a new class of bismuth cyclized CPPs with excellent cytosolic entry efficiencies, proteolytic stability, and potential compatibility with genetic encoding and recombinant production.
PMID:39223839 | PMC:PMC11610496 | DOI:10.1021/acs.molpharmaceut.4c00688
03 Sep 18:16
by Jianan Li
Brief Bioinform. 2024 Jul 25;25(5):bbae417. doi: 10.1093/bib/bbae417.
ABSTRACT
Cyclic peptides are versatile therapeutic agents that boast high binding affinity, minimal toxicity, and the potential to engage challenging protein targets. However, the pharmaceutical utility of cyclic peptides is limited by their low membrane permeability-an essential indicator of oral bioavailability and intracellular targeting. Current machine learning-based models of cyclic peptide permeability show variable performance owing to the limitations of experimental data. Furthermore, these methods use features derived from the whole molecule that have traditionally been used to predict small molecules and ignore the unique structural properties of cyclic peptides. This study presents CycPeptMP: an accurate and efficient method to predict cyclic peptide membrane permeability. We designed features for cyclic peptides at the atom-, monomer-, and peptide-levels and seamlessly integrated these into a fusion model using deep learning technology. Additionally, we applied various data augmentation techniques to enhance model training efficiency using the latest data. The fusion model exhibited excellent prediction performance for the logarithm of permeability, with a mean absolute error of $0.355$ and correlation coefficient of $0.883$. Ablation studies demonstrated that all feature levels contributed and were relatively essential to predicting membrane permeability, confirming the effectiveness of augmentation to improve prediction accuracy. A comparison with a molecular dynamics-based method showed that CycPeptMP accurately predicted peptide permeability, which is otherwise difficult to predict using simulations.
PMID:39210505 | PMC:PMC11361855 | DOI:10.1093/bib/bbae417
03 Sep 18:12
by Jun Liu, Yanhua Li, Kehui Zhou, Shijia Zhang, Yue Wang, Xiumei Wang, Xiabin Lan, Qixian Chen, and Yan Zhao

Bioconjugate Chemistry
DOI: 10.1021/acs.bioconjchem.4c00319
02 Sep 16:42
by Norman Metanis
Angew Chem Int Ed Engl. 2025 Feb 17;64(8):e202414256. doi: 10.1002/anie.202414256. Epub 2024 Nov 5.
ABSTRACT
Matrix metallopeptidase 7 (MMP7) plays a crucial role in cancer metastasis and progression, making it an attractive target for therapeutic development. However, the development of selective MMP7 inhibitors is challenging due to the conservation of active sites across various matrix metalloproteinases (MMPs). Here, we have developed mirror-image random nonstandard peptides integrated discovery (MI-RaPID) technology to discover innate protease-resistant macrocyclic peptides that specifically bind to and inhibit human MMP7. One identified macrocyclic peptide against D-MMP7, termed D20, was synthesized in its mirror-image form, D'20, consisting of 12 D-amino acids, one cyclic β-amino acid, and a thioether bond. Notably, it potently inhibited MMP7 with an IC50 value of 90 nM, and showed excellent selectivity over other MMPs with similar substrate specificity. Moreover, D'20 inhibited the migration of pancreatic cell line CFPAC-1, but had no effect on the cell proliferation and viability. D'20 exhibited excellent stability in human serum, as well as in simulated gastric and intestinal fluids. This study highlights that MI-RaPID technology can serve as a powerful tool to develop in vivo stable macrocyclic peptides for therapeutic applications.
PMID:39215490 | PMC:PMC11833282 | DOI:10.1002/anie.202414256